{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:56:35Z","timestamp":1761872195421,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T04:34:10Z","timestamp":1673584450000},"page":"168-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"23","author":[{"given":"Virginia O.","family":"Volpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2023.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.clml.2023.01.001_bib0002","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2023.01.001_bib0003","first-page":"3616","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood, J Am Society Hematol"},{"issue":"15","key":"10.1016\/j.clml.2023.01.001_bib0004","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2023.01.001_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2023.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0008","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2022-162326","article-title":"AML and MDS Classification according to who 2022 and international consensus classification: do we invent a babylonian confusion of languages?","volume":"140","author":"Huber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.01.001_bib0009","first-page":"2454","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood, J Am Society Hematol"},{"issue":"6","key":"10.1016\/j.clml.2023.01.001_bib0010","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.01.001_bib0011","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2021-149708","article-title":"The natural history of lower risk MDS: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia in patients with very low and low risk MDS according to the R-IPSS criteria","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.clml.2023.01.001_bib0012","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.01.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.clml.2023.01.001_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International working group for the prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V88.1.59.59","article-title":"Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age","volume":"88","author":"Busque","year":"1996","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2023.01.001_bib0016","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clml.2023.01.001_bib0017","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2023.01.001_bib0018","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2017.181","article-title":"CHIP, ICUS, CCUS and other four-letter words","volume":"31","author":"Bejar","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2014.09.010","article-title":"Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS","volume":"36","author":"Valent","year":"2012","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.clml.2023.01.001_bib0023","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.01.001_bib0024","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.01.001_bib0025","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1182\/blood-2021-146254","article-title":"Characteristics and clinical outcome of patients with clonal cytopenias of undetermined significance: a large retrospective multi-center international study","volume":"138","author":"Xie","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-021-00439-x","article-title":"Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study","volume":"11","author":"Xie","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0027","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.001_bib0028","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1182\/blood-2021-145853","article-title":"Treatment patterns and outcomes of patients with lower-risk myelodysplastic syndromes in the connect \u00ae myeloid disease registry","volume":"138","author":"Komrokji","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.01.001_bib0029","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.21269","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"83","author":"Bennett","year":"2008","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0030","first-page":"1096","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood, J Am Society Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0031","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0032","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstr\u00f6m-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.clml.2023.01.001_bib0033","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"J\u00e4dersten","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.01.001_bib0034","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/leu.2013.16","article-title":"Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents","volume":"27","author":"Kelaidi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.21316","article-title":"A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes","volume":"84","author":"Gotlib","year":"2009","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2023.01.001_bib0036","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin\u00a0+\u00a0granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.clml.2023.01.001_bib0037","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2023.01.001_bib0038","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.01.001_bib0039","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.V112.11.1647.1647","article-title":"Long-Term cytogenetic follow-up of MDS patients with 5q- treated within the MDS-003 (CC-5013-MDS-003) study: evolution to complex clones and progression to AML","volume":"112","author":"G\u00f6hring","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.001_bib0040","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0145-2126(07)70066-8","article-title":"C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion","volume":"31","author":"List","year":"2007","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-140339","article-title":"Phase 3 study of lenalidomide (LEN) Vs placebo in non-transfusion dependent (TD) low risk del(5q) MDS patients - interim analysis of the European Sintra-REV trial","volume":"136","author":"L\u00f3pez Cadenas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.001_bib0042","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2022-168718","article-title":"Evaluation of lenalidomide (LEN) Vs placebo in non-transfusion dependent low risk del(5q) MDS patients. final results of Sintra-REV phase III international multicenter clinical trial","volume":"140","author":"Cadenas","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0043","doi-asserted-by":"crossref","first-page":"9740","DOI":"10.1182\/blood-2022-168599","article-title":"Long-term evolution of somatic mutations in patients with del(5q) MDS early treated with lenalidomide in the sintra-rev clinical trial: safe and effecitive approach?","volume":"140","author":"Toribio Castell\u00f3","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.01.001_bib0044","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2023.01.001_bib0045","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2023.01.001_bib0046","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood.V128.22.223.223","volume":"128","author":"List","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0047","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0048","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood-2022-157489","article-title":"Overall survival and progression-free survival of patients following luspatercept treatment in the MEDALIST trial","volume":"140","author":"Santini","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.01.001_bib0049","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2023.01.001_bib0050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia","volume":"120","author":"Killick","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0051","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.01.001_bib0052","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2002-09-2867","article-title":"Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome","volume":"101","author":"Steensma","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0053","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care\u2013SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.01.001_bib0054","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2023.01.001_bib0055","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0056","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3324\/haematol.2019.219345","article-title":"Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis","volume":"105","author":"Maximilian","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0057","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0058","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.001_bib0059","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-133855","article-title":"Clinical efficacy and safety of oral decitabine\/cedazuridine in 133 patients with myelodysplastic syndromes (mds) and chronic myelomonocytic leukemia (cmml)","volume":"136","author":"Savona","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2023.01.001_bib0060","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2023.01.001_bib0061","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1182\/blood.V120.21.3833.3833","article-title":"Azacitidine treatment for lenalidomide (LEN)-resistant myelodysplastic syndrome (MDS) with del 5q","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.01.001_bib0062","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clml.2015.08.083","article-title":"Lenalidomide treatment for lower risk nondeletion 5q myelodysplastic syndromes patients yields higher response rates when used before azacitidine","volume":"15","author":"Zeidan","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"10.1016\/j.clml.2023.01.001_bib0063","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0064","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-dose decitabine versus low-dose azacitidine in lower-risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.clml.2023.01.001_bib0065","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1\u2013risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0066","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0067","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.01.001_bib0068","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Myelodysplastic Syndromes 2022."},{"issue":"14","key":"10.1016\/j.clml.2023.01.001_bib0069","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0070","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2021-153054","article-title":"IDH mutations are enriched in myelodysplastic syndromes patients with severe neutropenia: a potential targeted therapy","volume":"138","author":"Komrokji","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.001_bib0071","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2021-146932","article-title":"Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the idiome phase 2 study by the GFM group","volume":"138","author":"Sebert","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0072","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2021-147898","article-title":"Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the ideal phase 2 study by the GFM group","volume":"138","author":"Ades","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.01.001_bib0073","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron Chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.clml.2023.01.001_bib0074","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.01.001_bib0075","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2023.01.001_bib0076","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0077","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3343\/alm.2017.37.3.195","article-title":"Dysregulation of Telomere lengths and telomerase activity in myelodysplastic syndrome","volume":"37","author":"Park","year":"2017","journal-title":"Ann Lab Med"},{"issue":"3","key":"10.1016\/j.clml.2023.01.001_bib0078","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/gcc.20737","article-title":"Telomere shortening and chromosomal instability in myelodysplastic syndromes","volume":"49","author":"Lange","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0079","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.leukres.2005.03.006","article-title":"Telomerase activity in myelodysplastic syndromes","volume":"29","author":"G\u00fcrkan","year":"2005","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0080","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0081","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0082","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion\u2013burden patients with lower-risk myelodysplastic syndromes in a phase ii study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.01.001_bib0083","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0084","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0085","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2019-128714","article-title":"Roxadustat (FG4592; ASP1517; AZD9941) in the treatment of anemia in patients with lower risk myelodysplastic syndrome (LR-MDS) and low red blood cell (RBC) transfusion burden (LTB)","volume":"134","author":"Henry","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.001_bib0086","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2016.00151","article-title":"Unraveling the pathogenesis of MDS: The NLRP3 inflammasome and pyroptosis drive the MDS phenotype","volume":"6","author":"Sallman","year":"2016","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0087","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.cpcardiol.2021.100962","article-title":"Clonal hematopoiesis and cardiovascular diseases: the connection","volume":"47","author":"Mozzini","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"8","key":"10.1016\/j.clml.2023.01.001_bib0088","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a\u00a0mechanism involving the IL-1\u03b2\/NLRP3\u00a0inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2023.01.001_bib0089","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2021-147594","article-title":"Phase 1\/2 study of oral TP-0184 for the treatment of anemia in adults with low- or intermediate-risk myelodysplastic syndromes","volume":"138","author":"Verma","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.01.001_bib0090","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2022-159774","article-title":"Phase 1 results of the first-in-class CXCR1\/2 Inhibitor SX-682 in patients with hypomethylating agent failure myelodysplastic syndromes","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.001_bib0091","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"10.1016\/j.clml.2023.01.001_bib0092","first-page":"1039","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood, J Am Society Hematol"},{"issue":"7","key":"10.1016\/j.clml.2023.01.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J Exp Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:51Z","timestamp":1761871311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265023000022"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}